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Background & aims: Mortality resulting from influenza (flu) virus infections occurs primarily in the
elderly through declining immunity. Studies in mice have suggested beneficial effects of selenium (Se)
supplementation on immunity to flu but similar evidence is lacking in humans. A dietary intervention
study was therefore designed to test the effects of Se-supplementation on a variety of parameters of anti-
flu immunity in healthy subjects aged 50e64 years.
Methods: A 12-week randomized, double-blinded, placebo-controlled clinical trial (ClinicalTrials.gov
NCT00279812) was undertaken in six groups of individuals with plasma Se levels <110 ng/mL. Four
groups were given daily capsules of yeast enriched with 0 mg Se/day (SeY-0/d; n ¼ 20), 50 mg Se/
d (SeY-50/d; n ¼ 18), 100 mg Se/d (SeY-100/d; n ¼ 21) or 200 mg Se/d (SeY-200/d; n ¼ 23). Two groups
were given onion-containing meals with either <1 mg Se/d (SeO-0/d; n ¼ 17) or 50 mg Se/d (SeO-50/d;
n ¼ 18). Flu vaccine was administrated at week 10 and immune parameters were assessed until week
12.
Results: Primary study endpoints were changes in cellular and humoral immune responses. Sup-
plementation with SeY and SeO affected different aspects of cellular immunity. SeY increased Tctx-
ADCC cell counts in blood (214%, SeY-100/d) before flu vaccination and a dose-dependent increase
in T cell proliferation (500%, SeY-50/100/200/d), IL-8 (169%, SeY-100/d) and IL-10 (317%, SeY-200/d)
secretion after in vivo flu challenge. Positive effects were contrasted by lower granzyme B content
of CD8 cells (55%, SeY-200/d). SeO (Se 50 mg/d) also enhanced T cell proliferation after vaccination
(650%), IFN-g (289%), and IL-8 secretion (139%), granzyme (209%) and perforin (190%) content
of CD8 cells but inhibited TNF-a synthesis (42%). Onion on its own reduced the number of NKT
cells in blood (38%). These effects were determined by comparison to group-specific baseline
yeast or onion control groups. Mucosal flu-specific antibody responses were unaffected by Se-
supplementation.
Conclusion: Se-supplementation in healthy human adults with marginal Se status resulted in both
beneficial and detrimental effects on cellular immunity to flu that was affected by the form of Se, sup-
plemental dose and delivery matrix. These observations call for a thorough evaluation of the risks and
benefits associated with Se-supplementation.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).coupled dye; flu, influenza; IFN-g, interferon gamma; Ig, immunoglobulin; IL, interleukin; LAK, lymphokine activated
clear cells; NK, natural killer; Se, selenium; SeMet, selenomethionine; SeMSC, g-glutamyl-methylselenocysteine; SeY,
ecrosis factor alpha.
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Selenium status is known to influence ability of the immune
system to respond to infections [1]. Evidence for the importance
of adequate Se intakes is provided by the impact that Se defi-
ciency has on the immune system, reportedly reducing prolifer-
ation of T cells [2], lymphocyte-mediated toxicity and NK cell
activity [3], all of which are important for antiviral immunity.
While the mechanisms by which Se exerts its antiviral effects are
unknown, Se/selenoproteins regulate cellular redox balance and
it is known that the establishment and progression of viral in-
fections are influenced by the redox state of the host cell [4].
Dietary Se is mainly present in organic complexes, such as
selenomethionine (SeMet) found in meat, cereals and plant
foods, and Se-methylselenocysteine (SeMSC) in Se-accumulator
plants such as onions and brassica vegetables, with smaller
quantities of inorganic Se derived from dietary supplements. One
of the proposed consequences of marginal Se status is impaired
immune function. With regard to anti-viral response the benefits
of higher Se intake have been demonstrated solely in the recall
responses to polio virus vaccination of healthy volunteers with
marginal selenium status [5]. This prompted us to evaluate the
effects of Se supplementation on a set of immunological pa-
rameters that pertain to both cellular and humoral immunity to a
different type of virus, such as the influenza (flu) virus. The
reason for this investigation is twofold. First, the polio virus is an
enteric pathogen and does not undergo the rapid antigenic drifts
seen in flu virus; as such, the benefits in recall responses to
attenuated polio vaccination cannot therefore be extrapolated to
flu virus infections. Secondly, flu infection has very high socio-
economic cost worldwide [6] and to identify food supplements
with the ability to potentiate immunity in at risk populations,
such as the elderly and chronically ill may have an important
impact on overstretched healthcare systems worldwide. Indeed,
in annual flu epidemics 5e15% of the population is affected with
upper respiratory tract infections that result in three to five
million cases of severe illness and between 250,000 and 500,000
deaths every year around the world [6]. The aims of this study
were to measure both cellular and humoral immune responses to
flu vaccine in healthy older (50e64 years) individuals with
marginal Se status after Se supplementation.
2. Subjects and methods
2.1. Subjects and study design
A randomized, double-blind, placebo-controlled study was
undertaken in adults aged 50e64 years with suboptimal Se status
(plasma Se < 110 ng/mL), to determine the effects of Se supple-
mentation on immune responses to flu vaccine. The study was
approved by the Norfolk Research Ethics Committee (ref 05/
Q0101/32) and registered as a clinical trial (ClinicalTrials.gov
NCT00279812). Volunteers were excluded if they had abnormal
hematology, blood chemistry, blood pressure measurements, or
BMI <18.5 or >35 kg/m2. They had to be non-smokers, not on
prescription medication for a chronic ailment or taking any
immunosuppressive drugs, antacids or laxatives. Any dietary or
herbal supplements being used had to be forfeited from at least
one month prior to the start of the study and for its duration.
People that had donated blood within 16 weeks of the first study
sample and/or were due to do so less than 16 weeks after the last
study sample were excluded. Neither immunizations during the
study period nor antibiotic use from within four weeks prior to
starting the study until the study end were permitted. Concurrent
participation in another research project was discouraged.Anyone who needed more than 2 weeks' absence from the study
were also excluded. Allergy to eggs or egg products, chicken
protein, the antibiotic gentamicin or history of Guillain-Barre
syndrome were also exclusion criteria. More detailed information
can be found in Hurst et al. [7]. Briefly, each subject was randomly
assigned to one of six groups by the study scientists and given
tablets containing SeMet in yeast matrix (SeY) at a daily dose of
either 0 (SeY-0/d; n ¼ 20), 50 (SeY-50/d; n ¼ 18), 100 (SeY-100/d;
n ¼ 21) or 200 (SeY-200/d; n ¼ 23) mg Se or test meals three times
a week made with Se-enriched onions (SeO) containing SeMSC
with the equivalent of 50 mg Se/day (SeO-50/d; n ¼ 18) or unen-
riched onions (SeO-0/d; n ¼ 17), for a period of 12 weeks. Se-
containing yeast tablets were prepared and Se-enriched onions
were grown as described elsewhere [7]. A computerized random
number generator was used for the allocation of volunteers. The
double-blind coding was not revealed until the completion of final
data analyses.2.2. Flu vaccination process and monitoring of pre- and post-
vaccination responses
At week 10 participants were vaccinated with a trivalent influ-
enza vaccine (Solvay Pharmaceuticals, Weesp, The Netherlands)
developed according to World Health Organization (WHO) guide-
lines. Vaccines were administered intramuscularly in the deltoid
region of the arm by the study nurses. The flu vaccine strains used
were determined according to annual recommendations by the
WHO. Vaccines contained the following: influenza A strain subtype
H1N1/New Caledonia (years 1 and 2), Solomon Islands (year 3);
subtype H3N2/California (year 1), Wisconsin (years 2 and 3);
Influenza strain B subtype Jiangsu (year 1), Malaysia (years 2 and 3).
Strains of H1N1 (A), H3N2 (A) and B viruses were administered in
equal amounts (15 mg of each in 0.5 mL). Fasting blood samples
(65mL) were drawn at weeks 0 (baseline), 10 (Se-intervention, pre-
vaccination), 11 (Se-intervention, post vaccination week 1) and 12
(Se-intervention, post vaccination week 2). Enrollment and all
study procedures involving human volunteers were performed at
the Human Nutrition Unit at the Institute of Food Research, Nor-
wich, UK.2.3. Volunteer randomization and dietary intervention
Volunteers were randomly allocated to one of six study groups.
A computerized random number generator was used (URL: http://
www.randomizer.org/form.htm) to generate 3 digit numbers with
the group codes A, B, C, D, E or F to facilitate allocation of volun-
teers. This was done by the study statistician. Yeast supplements
were supplied in coded form as either A, B, C, or D. The supple-
ments were taken with a meal on a daily basis. Onions for the
study meals were grown at the University of Nottingham, Sutton
Bonington, Leicestershire, UK. Their Se content was analyzed by
inductively coupled mass spectroscopy. Study meals were also
blinded in that the onions supplied by the University of Notting-
ham were labeled simply as white or yellow onions. Meals made
with the yellow onions were designated group E and those made
with white onion as group F. Meals were prepared to contain the
right weight of onions to achieve 117 mg Se/meal and three meals
were consumed per week by each participant in group E or F as an
average of 50 mg Se/d. Although volunteers in the onion meal
groups could not be blinded, the type of onion in their meal was
blinded. The identities of intervention codes used were not known
to the researchers, volunteers, statistician or study nurses.
Randomization data were kept confidential until study end and
completion of data analyses.
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The Se doses used in our study were within the safe limits
suggested by the European Food Safety Agency [8]. Yeast supple-
ments and onions used to prepare test meals were supplied in
coded form to ensure that the trial remained double-blind [7]. Se-
yeast supplements containing 60% SeMet were manufactured,
packed and supplied by Pharma Nord (Vojens, Denmark) [9]. Since
the normal diet of all participants enlisted to the study was clearly
low in selenium (as evidenced by their low selenium status), meals
were not specified in the group given selenium-enriched yeast or
unenriched yeast tablets.
2.5. Isolation and culture of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (MNC) with a viability >95%
were prepared and cultured as described previously [10] in the
absence or presence of 0.2 mg/mL of H1N1 flu antigens appropriate
for each year of the study (Solway Healthcare, Southampton, UK).
All cultures were placed at 37 C in a humidified atmosphere of 5%
CO2 in air. Cells were harvested for analyses on days 3 or 5. Culture
supernatants were removed at day 5 and frozen at 80 C.
2.6. Flu vaccine-induced T cell proliferation
Cells cultured for 5 days, as described above, were stained with
CD3-FITC (Becton Dickinson, UK), washed in PBS (Sigma) and the
pellets resuspended in 75% (v/v) ethanol in distilled water and
stored at 20 C. Prior to data acquisition, samples were centri-
fuged, washed once with PBS and resuspended in PBS before
staining for 45 min with a propidium iodide reagent (DNA prep
reagent kit, Beckman Coulter, High Wycombe, UK). Data were ac-
quired and analyzed on a Beckman Coulter FC500 MPL flow cy-
tometer using MXP software. CD3þ T cells were identified after
doublet exclusion which was effected using a PI peak versus inte-
gral plot. All phases of the cell cycle were put together to give a
combined S, G2 and M value with a dual doublet discriminant and
CD3 gate. % CD3þ PIþ cells in unstimulated cultures were subtracted
from values derived for cells stimulated with flu antigens.
2.7. Enumeration of cytotoxic cell subsets in whole blood
Heparinized whole blood was stained with an antibody cocktail
comprising CD8-APC (Invitrogen, UK), CD16-FITC (Bec-
toneDickinson, Oxford, UK), CD56-PE (BectoneDickinson) and
CD3-energy coupled dye (ECD) (Beckman Coulter, High Wycombe
UK). In parallel, blood was stained with appropriate isotype control
antibodies. Erythrocytes were lysed with FACSLysing solution
(Becton Dickinson) andwashed once. Stained cells were kept at 4 C
and to enable subset enumeration 50 mL of Flow Count Fluoro-
spheres (Beckman Coulter) were added to each sample just before
same-day data acquisition on a Beckman Coulter FC500 MPL flow
cytometer.
2.8. Evaluation of perforin and granzyme expression
MNC cultured for 3 days in the presence of flu antigens were
fixed and permeabilized (Fix and Perm; Invitrogen) according to
the manufacturer's instructions before staining with either a
‘positive’ or a ‘negative’ antibody cocktail. The ‘positive’ mixture
comprised CD3-ECD (Beckman Coulter), CD8-allophycocyanin
(APC) (Invitrogen), anti-perforin-PE and anti-granzyme-FITC
(both from BectoneDickinson). The ‘negative’ mixture con-
tained the same antibodies except for isotype controls (Becton
Dickinson) as substitutes for perforin and granzyme antibodies.Cells were analyzed by flow cytometry (Beckman Coulter FC500
MPL).2.9. Cytokine quantification
Cytokines were measured in 5-day supernatants collected from
cells cultured in the presence of flu antigens as described above,
using a 4-plex Luminex assay for interleukin-8 (IL-8), interleukin 10
(IL-10), interferon-gamma (IFN-g) and tumor necrosis factor-alpha
(TNF-a) (Biorad, Hertfordshire, UK). The assay was performed ac-
cording to the manufacturer's instructions. Data were acquired and
analyzed on a Luminex 200 System (Applied Cytometry Systems,
Sheffield, UK).2.10. Measurement of immunoglobulins (Ig) G1 and G3 in serum
Serum flu-specific antibody titers were measured by standard
enzyme-linked immunosorbent assay (ELISA) using 96-well mi-
crotiter plates coated with 1 mg/mL flu antigens (Solvay Pharma-
ceuticals, Netherlands). Sera were diluted prior to use. Dilutions of
serum were incubated for 2 h on coated and blocked ELISA plates.
Horseradish peroxidase labeled detection reagents anti-human
IgG1 and anti-human IgG3 antibodies were purchased from Cam-
bridge Bioscience (Cambridge, UK). Absorbance values were
determined at 450 nm using a Benchmark Plus plate reader (Bio-
Rad, Hemel Hempstead, Herts., UK). Inter-plate variability was
monitored by including the same selected serum samples on each
plate.2.11. Measurement of IgA in saliva
Volunteers were asked not to clean their teeth immediately
before collection of saliva samples which were stored at 80 C.
Before use samples were thawed, vortexed and centrifuged at
800 g for 10min. The ELISA procedure usedwas similar to the one
described above except for the use of biotin-labeled anti-human
sIgA (Stratech Scientific, Newmarket, Suffolk, UK) instead of anti-
human IgG, followed by extravidin-peroxidase (Sigma, UK) as
detection reagents. Fold change in titers was calculated simply as
the ratio of final value to the initial value.2.12. Statistics
Primary endpoints were changes in cellular and humoral im-
mune responses; secondary endpoints were changes in selenium
status, Se-protein levels and Se-biomarkers (ClinicalTrials.gov
NCT00279812). This work focuses on the effects of Se on immune
function. Sample size was determined from previous studies [11,12]
and designed to give 80% power. In order to be able to detect a
range of 1 standard deviation between the groups with a power of
80%, a sample size of 144 (or 24 in each group) was considered to be
sufficient. This allowed a drop-out rate of 25%, in which 18 volun-
teers needed to complete the study in each group. A repeated
measures ANOVA was used to compare the means of matched
groups. Post-hoc multiple comparisons were made using Dunnett's
test, where comparisons were made with relevant group controls.
Inter-group base-line comparisons were made using one-way
ANOVA followed by post-hoc Tukey test. While meaningful linear
or polynomial (quadratic) regression data could not be derivedwith
only four data points, trend lines were constructed to visualize
treatment dose effects. Values in the text are means ± standard
errors of the mean (SEMs) unless otherwise stated. A test was
considered significant at P < 0.05.
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3.1. Patient recruitment and retention
In total, 310 study interviews were conducted and, 272 screen-
ings were carried out. In total 139 volunteers were excluded at the
screening stage, most failing as a result of blood or urine parame-
ters falling outside the accepted range (n ¼ 48). The next largest
cause of exclusion was high plasma Se (n ¼ 33). Other reasons
included personal situations (n ¼ 18), high blood pressure (n ¼ 13),
BMI > 35 (n ¼ 7), inability to withdraw blood (n ¼ 6), incompatible
medication or supplement (n¼ 5), not returning for re-screen (n¼ 4),
untimely vaccinations (n ¼ 2), BMI < 18 (n ¼ 1), allergy (n ¼ 1) and
unavailability (n ¼ 1). Finally, 133 volunteers began the study and
were randomly assigned into each of 6 study groups (Fig. 1) [7],
From these 14 participants discontinued their intervention due to
illness unrelated to the Se intervention study (n ¼ 14). Finally, 119
(54 men and 65 women) were retained until study completion.
3.2. Subject characteristics at baseline
Volunteers within each of the 6 study groups had similar de-
mographic and baseline characteristics (Table 1) [7]. Inter-group
variations at baseline for T cell proliferation, cytolytic subsets, cy-
tokines or immunoglobulins were not statistically significant.
3.3. Se dose-dependent increases in T cell proliferation to flu
challenge
At week 10 of supplementation, there were no group-specific
differences in the percentages of proliferating T cells withinFig. 1. Patient recruitment and retentioncultures of MNC challenged in vitro with flu antigens (Fig. 2A).
However, under similar culture conditions, both yeast and onion
Se-supplemented groups had significantly higher T cell prolifera-
tion following flu vaccination with peak proliferation occurring at
week 11 (P < 0.05). In order to visualize any Se dose effects on T cell
proliferation above those induced by flu vaccination, linear or
polynomial trend lines were constructed for data derived from the
SeY groups (Fig. 2B). It was not possible to construct similar curves
for the SeO groups as only one dose of Se was used. These clearly
show a trend towards higher proliferation within the SeY-100
group at week 11 than that of SeY-50 or SeY-200 groups. These
data demonstrate that the ability of Se to enhance T cell recall re-
sponses to flu is influenced by the supplemental dose.3.4. Se supplementation and delivery matrix affect blood cytolytic
cells
Initially we monitored the effects of Se intake on whole blood
absolute counts of a variety of large granular lymphocyte (LGL)
subsets (Supplementary Table 1). Numbers of NKT cells at baseline
did not differ between yeast and onion study groups, but at week
10 the SeO-0/d unsupplemented onion group had significantly
fewer NKT cells/mL blood than at baseline (P < 0.05) (Fig. 3A).
Immunization with flu vaccine had no influence on this matrix
effect. At the same time period, before flu vaccination there were
higher numbers of Tctx-ADCC cells/mL blood in the SeY-100/
d group. Supplementation with Se, irrespective of its form and
supplemental dose, did not have any effect on the number of any
of the additional cytotoxic cell subsets included in our investiga-
tion. These remained unchanged throughout the study period in
all groups (Supplementary Fig. 1).is described (M, Male; F, Female).
Table 1
Characteristics of study participants at base-line.a
Yeast groups Onion groups
SeY-0/d
(n ¼ 20)
SeY-50/d
(n ¼ 20)
SeY-100/d
(n ¼ 21)
SeY-200/d
(n ¼ 23)
SeO-0/d
(n ¼ 17)
SeO-50/d
(n ¼ 18)
Age (years) 55.8 ± 3.9
(50e62)
56.5 ± 4.6
(50e64)
58.4 ± 3.9
(52e64)
56.1 ± 3.9
(50e64)
58.2 ± 5.1
(50e64)
57.7 ± 4.2
(52e65)
Sex (men/women) 10/10 9/9 11/10 11/12 6/11 6/12
bBMI (kg/m2) 25.0 ± 2.7
(22.0e33.0)
26.1 ± 3.0
(19.5e33.0)
26.3 ± 3.9
(20.0e33.5)
25.9 ± 3.8
(20.5e34.5)
26.6 ± 4.1
(20.0e21.5)
26.1 ± 2.4
(21.5e30.5)
a No significant differences were noted between the groups at baseline.
b BMI values are means ± SEMs.
Fig. 2. Proliferating T cells in isolated mononuclear cells cultured for 5 days with flu antigens. Weeks 0 and 10 samples were respectively collected before Se supplementation or flu
vaccination. Panel A shows group specific differences throughout the study period. Panel B shows the same data as Se dose-associated trends by linear or polynomial fit. Values are
means ± SEMs; *different from relevant control group (P < 0.05). SeY-0/d, n ¼ 10; SeY-50/d, n ¼ 9; SeY-100/d, n ¼ 28; SeY-200/d, n ¼ 15; SeO-0/d, n ¼ 12; SeO-50/d, n ¼ 14. SeO,
selenium onion; SeY, selenium yeast.
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We have evaluated the influence of Se on granzyme B and
perforin present within cytolytic granules on individual special-
ized CD8þ cytolytic subsets. In comparison with the SeY-0/
d control group, we observed lower granzyme content within
CD8 cells from the SeY-200/d group at week 10 (Fig. 4A). This
effect can be considered to be due to Se-supplemental dose since
it was observed before flu vaccination and apparent only at a
supplemental dose of 200 mg/day. Vaccination did not reverse
this decline. In contrast, CD8 cells from the SeO-50/d group had
significantly more granzyme B at week 12 (Fig. 4A) and more
perforin at week 11 (Fig. 4B) than the control group. Taken
together, these data suggest that beneficial or detrimental effects
on the production of cytolytic enzymes, which are importanteffector molecules involved in anti-viral defense, depends on
dosage and form of Se intake.
3.6. The dose and form of Se intake affect cytokine secretion in vitro
Cytokine secretion patterns are shown in Fig. 5. To remove
differences between groups at baseline (week 0), these values have
been subtracted from those derived at subsequent time points.
Negative values seen are relative to baseline. Post-vaccination at
week 11, both SeY-100/d and SeO-50/d supplemented groups had
produced significantly more IL-8 than their control groups
(Fig. 5A). While no further increases were seen within the SeO-50/
d group, rises in IL-8 production were sustained within the SeY-
100/d group up to week 12 (Fig. 5A). Although a clear dose-
dependent trend is seen in IL-10 production within the SeY-100/
Fig. 3. Effect of Se supplementation on (A) NKT and (B) Tctx-ADCC cell counts/mL blood. Weeks 0 and 10 samples were respectively collected before Se supplementation or flu
vaccination. Values are means ± SEMs; *different from relevant control group (P < 0.05). SeY-0/d, n ¼ 20; SeY-50/d, n ¼ 20; SeY-100/d, n ¼ 21; SeY-200/d, n ¼ 23; SeO-0/d, n ¼ 17;
SeO-50/d, n ¼ 18. NKT, natural killer T.; Tctx-ADCC, T cells that mediate antibody-dependent cell cytotoxicity, SeO, selenium onion; SeY, selenium yeast.
Fig. 4. Granzyme Bþ (A) and perforinþ (B) CD8 subsets within isolated mononuclear cells cultured for 3 days with flu antigens. Weeks 0 and 10 samples were respectively collected
before Se supplementation or flu vaccination. Values are means ± SEMs; *different from relevant control group (P < 0.05). SeY-0/d, n ¼ 15; SeY-50/d, n ¼ 12; SeY-100/d, n ¼ 16; SeY-
200/d, n ¼ 19. SeO-0/d, n ¼ 12, SeO-50/d, n ¼ 16. SeO, selenium onion, SeY, selenium yeast.
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bility within the group (Fig. 5B). Significantly larger amounts of
this cytokine were noted after flu vaccination in the SeY-200/
d group at week 11 and levels were maintained up to week
12. Only the Se-O-50/d group showed higher IFN-g synthesis
after vaccination at week 11 and this was followed by a decline
by week 12 (Fig. 5C). In contrast, the SeO-50/d group showedreduced levels of TNF-a secretion compared to its control group
(Fig. 5D).
3.7. Se did not affect in vivo antibody responses to flu vaccine
Flu-specific antibody titers of systemic IgG1 (Fig. 6A) and IgG3
(Fig. 6B) and mucosal (salivary) IgA (Fig. 6C) measured by ELISA
Fig. 5. Secreted protein concentrations in supernatants from isolated mononuclear cells cultured for 5 days with or without flu antigens. Weeks 0 and 10 samples were respectively
collected before Se supplementation or flu vaccination. In order to account for different baseline (week 0) values these have been subtracted from subsequent time points. Values
are means ± SEMs; *different from relevant control group (P < 0.05). SeY-0/d, n ¼ 17; SeY-50/d, n ¼ 15; SeY-100/d, n ¼ 18; SeY-200/d, n ¼ 19; SeO-0/d, n ¼ 13; SeO-50/d, n ¼ 16. SeO,
selenium onion; SeY, selenium yeast.
Fig. 6. Titers of flu-specific serum IgG1 (A,D), serum IgG3 (B) and fold change in salivary IgA (C). Weeks 0 and 10, samples were respectively taken before Se supplementation or flu
vaccination. 1, week 0; 2, week 10; 3, week 11; 4, week 12. Values are means ± SEMs for serum IgG (A,B); *different from relevant control group (P < 0.05). SeY-0/d, n ¼ 17; SeY-50/d,
n ¼ 16; SeY-100/d, n ¼ 19; SeY-200/d, n ¼ 21; SeO-0/d, n ¼ 15; SeO-50/d, n ¼ 17. SeO, selenium onion; SeY, selenium yeast.
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observed in serum IgG1 and IgG3 levels could be ascribed only to
in vivo stimulation by flu vaccination and not Se supplementation.
This is more evident in the trend lines shown for serum IgG1
(Fig. 6D). Similar trends were seen for serum IgG3 production (data
not shown). There was no change in salivary IgA measured as fold
change from baseline.
4. Discussion
This study was undertaken to assess the effects of Se-
supplementation on a comprehensive set of parameters of both
cellular and humoral immunity to influenza in older subjects. Their
baseline plasma Se levels between 92 and 98 ng/mL were deemed
to reflect marginal Se status despite being within stated normal
range because plasma Se concentration is subject to large effects of
dietary Se species. Therefore, it cannot be considered a direct
marker of the functional Se body pool. Instead, the level of sele-
noprotein P is more informative as it is responsive to different
forms of Se intake [13] and the point at which it reaches a plateau in
response to increasing doses of Se is considered indicative of an
adequate supply of Se to all tissues [14]. Selenoprotein P levels
reach saturation in plasma at a Se concentration of 120 ng/mL [7]
which is higher than the plasma Se levels of any volunteer
recruited onto our study. Details of the doseeresponse relations for
different forms of seleniumwith regard to plasma Se levels, platelet
glutathione peroxidase activity and selenoprotein P status are
described elsewhere [7].
The main findings of this work are that Se-supplementation
may have both beneficial and detrimental effects on cellular im-
munity and that these effects are largely dependent on the form of
Se and the supplemental dose. As Se up-regulates the expression of
many cell cycle-related genes to promote cell proliferation [15], we
tested proliferative responses to in vitro challengewith flu antigens.
While we examined total T cell proliferation, it is known that pro-
liferative responses to flu vaccine are generally higher within CD4
than CD8 T cell subsets [16,17]. At the pre-vaccination 10-week
period Se supplementation did not enhance T cell proliferation
above that seen in cultures stimulated at baseline. However, these
responses were boosted through flu vaccination, with significantly
higher T cell proliferation in the Se-Y/100/d group. As a possible
explanation for the increase in cell proliferation at this particular
dose of Se-yeast, in hepatocytes it has been shown that at this dose
Se induces a greater amount of protein per cell and an increase in
cellular GSSG-Rd (glutathione reductase) activity than 50 mg/d Se-
yeast. Se affects all “synthetic” stages of the cell cycle and
elevated GSSG or the GSSG:GSH (oxidized:reduced glutathione)
ratio may explain the anti-proliferative effects of higher doses of Se
on cells [16,18]. These data nevertheless show that at certain sup-
plemental doses, Se-yeast can enhance T cell proliferative re-
sponses to viral challenge.
The importance of using an appropriate Se dose was further
highlighted by analysis of cytolytic enzymes. Following supple-
mentation with Se-yeast at 200 mg/day, fewer granzymeþ CD8 cells
were noted only within this group suggesting that a higher sup-
plemental dose may not be beneficial. Meanwhile, at a dose of
50 mg/day Se-onion increased both granzyme and perforin content
of CD8 cells. So, both dose and form of Se used in supplementation
can have different effects. Since cytotoxic granule-mediated killing
by CTL occurs within hours of target cell recognition [19] and
perforin up-regulation occurs within hours of activation [20], it is
unlikely that this was an immediate consequence of loss or gain
through cytolytic activity.
There is no doubt that Se plays an important role in nutritional
sufficiency and immunological integrity and it has been found thatalthough plasma Se levels remained relatively unchanged following
a daily intake of Se-onion in meals [7], supplementation with Se-
onion up-regulated the expression of several selenoprotein genes,
including selenoprotein S [21] that is involved in several aspects of
immune responses [22]. Importantly, the latter observation lent
support for the relationship between Se status and immune func-
tion [21]. However, our study signals caution when attributing
changes in expression of selenoprotein genes with Se supplemen-
tation alone. Through adverse effects of onions alone on NKT cell
numbers, it is possible that the matrix used for delivery of Se can
somehow interfere with its immunoregulatory properties, either to
enhance or otherwise. For example, the presence of phytochemicals
in onions should be considered. These include organosulfur com-
pounds, flavonoids and pigments that are believed to mediate ef-
fects through different modes of action [23e26]. Overall, onions
have anti-inflammatory activity through inhibition of the proin-
flammatory cyclooxygenase and lipoxygenase enzymes, alongside
inhibition of eicosanoid (e.g. prostaglandins) biosynthesis [25] thus
affecting various immunological parameters. Inhibition of TNF-a
secretion by Se-onion could be a combined anti-inflammatory ef-
fect of onion plus Se. The flavonoids in onions also inhibit both
cytosolic and membrane tyrosine kinases that are involved in a
variety of functions including signal transduction [27]. While these
effects of onions may give them their anti-cancer properties, they
may have some unwanted effects on immune cells. With regard to
yeast as a matrix for Se delivery, Saccharomyces cerevisiae in the
Pharma Nord products used in our study is a potential source of
beta 1,3/1,6 glucans, which can prime the innate immune system.
Our data do suggest that the matrix used for delivery of Se should
be carefully selected. Furthermore, a lack of data on the effects of Se
on Ab responses to flu virus in humans prompted us to assess both
mucosal and systemic Ab response following Se supplementation.
In agreement with previous animal study that showed no changes
in levels of flu-specific Abs between Se-deficient and -adequate
mice [28], we did not observe any Se-associated increase in flu-
specific Ab response. This would confirm that Se affects cell-
mediated immunity to a greater extent than humoral anti-
influenza responses.
Overall, our study demonstrated that the effect of Se supple-
mentation is context dependent. For example, a dose of 200 mg/day
Se-yeast both enhanced IL-10 secretion and reduced the numbers
of granzymeþ CD8 cells in blood; thus it is possible that these two
effects act together to inhibit anti-viral responses. Similarly, Se-
onion both increased the numbers of granzymeþ and perforinþ
CD8 cells but reduced the numbers of NKT-cells in blood. Thus, our
evidence does not support the simple assumption that a Se con-
centration that is beneficial for one immune parameter will be
beneficial for all. It also showed that two important effector func-
tions of anti-viral immunity, that is antigen-specific T cell prolif-
eration and T cell content of cytotoxic granules, are differentially
regulated by Se-supplementation. The findings that when used as a
supplement, Se has a narrow effective range and might even be
detrimental raises questions about dietary recommendation. While
Se deficiency is known to have consequences on the health status,
our study shows that higher levels of se supplementation may also
have a negative impact on health. That is not to undermine the
importance of host Se status; indeed in mice lower baseline levels
of Se have been shown to contribute to the emergence of new flu
strains through avirulence to virulence transformation [5,29]. We
do not knowwhat role the immune response plays in these changes
or how adequate Se status would have affected the immune pa-
rameters examined in our study. In countries like the United
Kingdom, the generally low selenium status has been used as an
argument to promote supplementation practice; however, our
study suggests that it may be prudent to thoroughly evaluate the
K. Ivory et al. / Clinical Nutrition 36 (2017) 407e415 415risks and benefits associated with Se supplementation especially in
segments of the population particularly vulnerable to influenza
infection, such as the elderly and chronically ill.
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